Rimegepant Saves Costs Over Lasmiditan in Migraine Care

Research Summary

A recent study published in Expert Review of Pharmacoeconomics & Outcomes Research explored the costs of adverse events for acute migraine treatments using rimegepant (RIM) versus lasmiditan (LAS) in Spain. Utilizing probabilistic modeling and Monte Carlo simulations, the study found that RIM saves €613 per patient over 6 months compared to LAS. A separate analysis showed RIM saves €697 per patient over 12 months. The study concluded that RIM has a favorable safety profile, leading to 100% probability of cost savings for the Spanish National Health System across all scenarios analyzed, thereby conserving healthcare resources effectively.

Study Details

📄 Title: Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.

👥 Research Team: Santos Lasaosa S et al.

📚 Published In: Expert Rev Pharmacoecon Outcomes Res

📅 Publication Date: 2026 Jan 9

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.